non-small cell lung cancer

ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm
Fierce Pharma
Sun, 06/4/23 - 04:22 pm
ASCO 2023
Merck
Keytruda
non-small cell lung cancer
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Fierce Pharma
Wed, 05/31/23 - 06:59 pm
Yuhan
cancer
Boehringer Ingelheim
Takeda
HER2 inhbitor
non-small cell lung cancer
Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023
BioSpace
Tue, 05/30/23 - 09:47 am
Hummingbird Biosciences
HMBD-002
cliincal trials
ASCO 2023
triple-negative breast cancer
non-small cell lung cancer
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
Fierce Pharma
Thu, 05/25/23 - 08:33 pm
ASCO 2023
Merck
Keytruda
Novartis
Kisqali
non-small cell lung cancer
early breast cancer
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
BioSpace
Wed, 04/19/23 - 11:21 am
Bridge Biotherapeutics
BBT-207
AACR
non-small cell lung cancer
AACR: AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate
Fierce Pharma
Sun, 04/16/23 - 11:22 pm
AstraZeneca
AACR
Imfinzi
non-small cell lung cancer
Pragmatica: Lung cancer trial tests streamlined design, inclusive eligibility
RAPS.org
Wed, 04/12/23 - 10:29 pm
Project Pragmatica
National Cancer Institute
non-small cell lung cancer
clinical trials
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Thu, 03/16/23 - 07:02 pm
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec
Fierce Pharma
Mon, 12/19/22 - 12:29 pm
AstraZeneca
Imfinzi
lung cancer
non-small cell lung cancer
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
Fierce Pharma
Mon, 12/19/22 - 11:02 am
Eagle Pharmaceuticals
Pemfexy
Eli Lilly
mesothelioma
non-small cell lung cancer
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
BioSpace
Sun, 12/4/22 - 01:17 pm
Mirati Therapeutics
clinical trials
M&A
non-small cell lung cancer
sitravantinib
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Thu, 12/1/22 - 07:11 pm
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Fierce Pharma
Thu, 12/1/22 - 10:55 am
Roche
Tecentriq
clinical trials
non-small cell lung cancer
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
Fierce Pharma
Wed, 11/30/22 - 07:58 pm
GSK
Merck
Jemperli
Keytruda
clinical trials
non-small cell lung cancer
Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease
Fierce Biotech
Mon, 11/28/22 - 07:37 pm
Gilead Sciences
Arcus Biosciences
clinical trials
domvanalimab
zimberelimab
non-small cell lung cancer
Lyvgen and BMS partner for Phase II lung cancer antibody trial
Clinical Trials Arena
Mon, 11/28/22 - 10:18 am
Lyvgen
Bristol Myers Squibb
clinical trials
LVGN7409
non-small cell lung cancer
AZ claims another Imjudo approval, in big first-line NSCLC market
Pharmaphorum
Fri, 11/11/22 - 10:53 am
AstraZeneca
FDA
Imjudo
non-small cell lung cancer
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Wed, 11/9/22 - 10:38 am
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Fierce Biotech
Thu, 11/3/22 - 11:10 am
Gilead Sciences
ARCUS
clinical trials
Merck
Keytruda
domvanalimab
zimberelimab
non-small cell lung cancer
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Endpoints
Mon, 10/31/22 - 04:15 pm
Daiichi Sankyo
AstraZeneca
Enhertu
breast cancer
non-small cell lung cancer

Pages